These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28716884)

  • 1. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine.
    Screaton G; Mongkolsapaya J
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
    Galula JU; Salem GM; Chang GJ; Chao DY
    Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
    de Silva AM; Harris E
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines licensed and in clinical trials for the prevention of dengue.
    Torresi J; Ebert G; Pellegrini M
    Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.
    Whitehead SS; Subbarao K
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.
    Borges MB; Marchevsky RS; Carvalho Pereira R; da Silva Mendes Y; Almeida Mendes LG; Diniz-Mendes L; Cruz MA; Tahmaoui O; Baudart S; Freire M; Homma A; Schneider-Ohrum K; Vaughn DW; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
    PLoS Pathog; 2019 Apr; 15(4):e1007721. PubMed ID: 31009499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue vaccines: Are they safe for travelers?
    Halstead SB; Aguiar M
    Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses.
    Silva JVJ; Lopes TRR; Oliveira-Filho EF; Oliveira RAS; Durães-Carvalho R; Gil LHVG
    Acta Trop; 2018 Jun; 182():257-263. PubMed ID: 29551394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine.
    Wang R; Gao N; Li Y; Fan D; Zhen Z; Feng K; Chen H; An J
    Front Cell Infect Microbiol; 2019; 9():147. PubMed ID: 31139577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a dengue vaccine: progress to date and remaining challenges.
    Guy B; Almond JW
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):239-52. PubMed ID: 17889365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.